Posted by Michael Wonder on 06 Jul 2023
IPS Heart receives US FDA rare paediatric drug designation for ISX9-CPC stem cell therapy for treatment of cardiomyopathy associated with Danon disease
6 July 2023 - Marks third rare paediatric drug designation granted by FDA for pipeline candidate.
IPS Heart today announced that the US FDA awarded a third rare paediatric drug designation for its product candidate, ISX9-CPC, for treatment of cardiomyopathy associated with Danon disease.
